News | September 21, 2010

Counterclaim Filed in Patent Infringement Case

September 21, 2010 - Patent infringement claims by St. Jude Medical Systems against the Volcano Corporation are without merit, the company said Tuesday.

In a filing made in the United States District Court for the District of Delaware, Volcano denies allegations that its PrimeWire products infringe any valid claim of St. Jude's asserted patents. Furthermore, as described in detail in its answer, the company believes that two of the asserted St. Jude patents are unenforceable because they were obtained through acts of fraud on the United States Patent and Trademark Office (USPTO).

Specifically, Volcano believes that the individuals involved in securing these two patents knowingly withheld from the USPTO a patent describing the pioneering work of scientists at Volcano's predecessor company, Cardiometrics.

In addition, Volcano has alleged that St. Jude's PressureWire products and its RadiAnalyzer Xpress infringe three Volcano patents. In its counterclaim, Volcano is seeking injunctive relief and monetary damages. The company intends to demonstrate that St. Jude has adopted Volcano's technology to enable it to compete in the rapidly expanding sensor-equipped guidewire field.

"Volcano believes that it, not St. Jude or Radi Medical, has led the way in fractional flow reserve (FFR) technology by developing the first guide wires to incorporate a solid state pressure sensor, the WaveWire. Volcano's predecessor company was also the first to introduce a guide wire containing a solid-state sensor for measuring intravascular flow rates, the FlowWire. Volcano believes that the Cardiometrics patents and Volcano's related innovative products render St. Jude's asserted claims invalid," said Scott Huennekens, CEO of Volcano.

"As the innovator of these guide wire technologies, Volcano intends to set the historical record straight and will vigorously defend against St. Jude's claims. Volcano respects the intellectual property rights of its competitors and expects them do to the same," he added.

For more information please visit: www.volcanocorp.com

Related Content

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

The Acist Navvus II Rapid Exchange FFR MicroCatheter delivers even more flexibility and a streamlined crossing profile to assess complicated lesions.

News | FFR Technologies | July 09, 2020
July 9, 2020 – Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist Navvus II
The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

The Medis QFR technology allows non-invasive functional FFR assessment of coronary flow based on standard X-ray angiographic images in the cath lab without the use of a pressure wire.

Feature | FFR Technologies | July 07, 2020 | Dave Fornell, Editor
An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

An OCT intracoronary image showing instent restenosis. The white spots in the vessel wall casting shadows are the stent struts. OCT image data might be used in the future to assess FFR to determine the severity of lesions and determine if they need to be stented.

News | FFR Technologies | May 15, 2020
May 15, 2020 – A late-breaking study aimed to evaluate whether...
In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image.

In June 2019, Medis received clearance from the U.S. Food and Drug Administration for its QAngio XA 3D technology (QFR). The FFR-angio technology can show the FFR readings in a 3-D image and overlaid on a fluoro image. 

Feature | FFR Technologies | August 05, 2019 | Dave Fornell and Greg Freiherr
New technologies have been developed that may replace the traditional pressure wires and adenosine to assess the...
First Prospective Registry Confirms FFR Impacts CAD Treatment Plans
News | FFR Technologies | June 17, 2019
A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans...
One in Four Patients Have Residual Ischemia Following PCI
News | FFR Technologies | March 20, 2019
At the American College of Cardiology’s (ACC) annual meeting, March 16-18 in New Orleans, Philips announced the results...
HeartFlow Analysis Successfully Stratifies Heart Disease Patients at One Year
News | FFR Technologies | March 19, 2019
Late-breaking results confirm the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis enables...
Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. Abbott FFR.

Abbott's Resting Full-cycle Ratio (RFR) intravascular diagnostic test is a newer type of fractional flow reserve (FFR) physiologic assessment. RFR is used to help identify significant narrowings of coronary arteries to determine the need for a stent or if a patient can be treated medically. 

Technology | FFR Technologies | March 06, 2019
March 5, 2019 –  The U.S.
CathWorks FFRangio System Receives U.S. FDA Clearance
Technology | FFR Technologies | December 21, 2018
CathWorks announced that its FFRangio System received U.S. Food  and Drug Administration (FDA) 510(k) clearance. The...